Araxes Pharma LLC

Intellikine LLC

Irm LLC

Infinity Pharmaceuticals, Inc.

Kura Oncology, Inc.

University of California

Skyworks Solutions, Inc.

Novartis Ag

University of Michigan

Janssen Biotech, Inc.

Millennium Pharmaceuticals Limited

Meta Platforms, Inc.

Curagen Corporation

Qualcomm Incorporated

Takeda Pharmaceutical Company Limited

Yi Liu

Pingda Ren

Liansheng Li

Jun Feng

Katrina Chan

Troy Edward Wilson

Tao Wu

Yuan Liu

Yun Long

Christian Rommel

Alfredo C Castro

Catherine Anne Evans

Nathanael Schiander Gray

Daniel A Snyder

Martin R Tremblay

Tao Liu

Andre Lescarbeau

Shuli You

Somarajannair Janardanannair

Taebo Sim

Pascal Furet

Anthony James Lobianco

Howard E Chen

Yi Wang

Jolanta Grembecka

Tomasz Cierpicki

Dmitry Borkin

Jonathan Pollock

Donald Karanewsky

Hoang Mong Nguyen

Simon F Campbell

Matthew Sean Read

Vito Guagnano

Shifeng Pan

Qiang Ding

Baogen Wu

Zhiyong Chen

Xiaolin Li

Valentina Molteni

Tetsuo Uno

Guobao Zhang

Bing Li

Jon Christopher Loren

Juliet Nabakka

Donatella Chianelli

Xia Wang

Mack Flinspach

Alan Wickenden

Xiuwen Zhu

Ruo W Steensma

Xiaoming Li

Xiaodong Liu

Jiqing Jiang

Katayoun Jessen

Xin Guo

Bo He

William John Domino

Stephane Richard Marie Wloczysiak

Bipul Agarwal

Yongqin Wan

Duxin Sun

Xing Wang

Yongping Xie

Michael J Hunter

Szymon Klossowski

Joseph Schoepfer

Michael Martin

Dai Cheng

Hongzhi Miao

Matthew Patricelli

Qinghao Xu

Yang Yang

Ge Wang

Robert Francis Darveaux

Pamela Ann Albaugh

Paul William Manley

Guido Bold

Tao Jiang

Kevan M Shokat

Yun He

Marc Lang

Giorgio Caravatti

Werner Breitenstein

Yuan Mi

Andrew Gaheem Hsieh

Advait Suresh Nagle

Xiaohui He

Alexander Star

Badry Bursulaya

Kunyong Yang

Ha-Soon Choi

Yi Fan

Nathanael S Gray

Carsten Spanka

Xiaojie Zhang

Zhicheng Wang

Joel S Bader

Patricia Imbach

Robert Oliver Burns Zeldin

Ludek Ridvan

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

Covalent inhibitors of KRAS G12C

The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.

Heterocyclic compounds and uses thereof

An electronic package is provided. The electronic package comprises a substrate having a first side and a second side, the substrate configured to receive one or more electronic components; a first electronic component mounted to the first side of the substrate; a first mold structure extending over at least part of the first side of the substrate; a group of through-mold connections provided on the first side of the substrate, the through-mold connections substantially formed of non-reflowable electrically conductive material; the first mold structure substantially encapsulating the group of through-mold connections; the group of through-mold connections exposed through the first mold structure. An electronic device comprising such an electronic package is also provided. A method of manufacturing such an electronic package is also provided.

Electronic package and method for manufacturing an electronic package

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R, R, R, R, R, R, R, R, R, R, A, B, G, G, L, L, m, m, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Substituted quinazoline compounds and methods of use thereof

A packaged semiconductor module comprises a substrate having a ground plane, an electronic device mounted on a surface of the substrate, a bond pad disposed on the surface of the substrate and electrically connected to the ground plane, a mold compound covering the electronic device, a conductive post disposed on a side of the electronic device, the conductive post extending from the bond pad and at least partially through the mold compound, and a conductive layer disposed on the mold compound and electrically coupled to the conductive post and to the ground plane, the conductive post, the conductive layer, and the ground plane together forming the integrated electromagnetic interference shield, the conductive post extending from the bond pad to the conductive layer in a direction perpendicular to a plane defined by the surface of the substrate.

Application of conductive via or trench for intra module EMI shielding

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, have the following structure: wherein A, L, L, Q, R, R, R, R, R, R, R, R, Y, and Z are as exemplified herein. Pharmaceutical compositions comprising such compounds, methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, and methods associated with preparation of such compounds are also provided.

Substituted piperazines as inhibitors of KRAS G12C

The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.

Macrocyclic heterocycles and uses thereof

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R, L, L, L, A, A, A, A, G, G, E, W, X, Y, Z, m, and n are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer

The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of certain oncogenic proteins.

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R, R, R, R, R, R, G, G, L, L, m, m, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Substituted quinazolines as inhibitors of KRAS G12C

The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.

Thienopyrimidine and thienopyridine compounds and methods of use thereof

Devices for fabrication of shielded modules. In some embodiments, a carrier assembly can be provided for processing of packaged modules. The carrier assembly can include a plate having a first side that defines a plurality of openings, and an adhesive layer implemented on the first side of the plate. The adhesive layer can define a plurality of openings arranged to substantially match the openings of the plate, with each opening of the adhesive layer being dimensioned such that the adhesive layer is capable of providing an adhesive engagement between an underside perimeter portion of a package and a perimeter portion about the corresponding opening of the first side of the plate.

Devices for fabrication of shielded modules

Growing community of inventors

San Diego, CA, United States of America

Yi Liu